NCT06962371View on ClinicalTrials.gov

Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Transcatheter Aortic Valve Implantation (TAVI)Aortic Valve StenosisTranscatheter Aortic Valve Replacement
Interventions
DEVICE

cerebral embolic protection

Use of Transverse Medical Inc. Point-Guard CEP device.

Trial Locations (1)

3168

RECRUITING

Victorian Heart Hospital, Clayton

Sponsors
All Listed Sponsors
lead

Transverse Medical, Inc.

INDUSTRY

collaborator

Medical Metrics Diagnostics, Inc

INDUSTRY

collaborator

Monash Health

OTHER

collaborator

Transverse Medical Australia

UNKNOWN

collaborator

Ascend Clinical

UNKNOWN

NCT06962371 - Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN) | Biotech Hunter | Biotech Hunter